Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130225174124im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
Condition | Intervention | Phase |
---|---|---|
Sarcoma |
Drug: liposomal daunorubicin citrate |
Phase 1 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines |
- Effect of liposomal daunorubicin citrate on Kaposi's sarcoma-associated herpes virus (KSHV) viral gene expression in tumors [ Time Frame: 24-48 hours after the first treatment ] [ Designated as safety issue: No ]
- Effect of treatment on KSHV viral gene expression in peripheral blood mononuclear cells [ Time Frame: 24-48 hours after treatment on Day 1/cycle 1, Day 8/cycle 1, and Day 29/cycle 3 ] [ Designated as safety issue: No ]
- Effect of treatment on KSHV viral load in plasma [ Time Frame: 24-48 hours after treatment on Day 1/cycle 1, Day 8/cycle 1, and Day 29/cycle 3 ] [ Designated as safety issue: No ]
Enrollment: | 14 |
Study Start Date: | September 2008 |
Study Completion Date: | November 2011 |
Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: liposomal daunorubicin citrate
40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
|
Drug: liposomal daunorubicin citrate
40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
Other Name: DaunoXome
|
Detailed Description:
OBJECTIVES:
Primary
- Determine the effect of liposomal daunorubicin citrate on Kaposi's sarcoma-associated herpes virus (KSHV) viral gene expression in tumors of patients with HIV-related Kaposi's sarcoma.
Secondary
- Determine the effect of this drug on KSHV viral gene expression in peripheral blood mononuclear cells.
- Determine the effect of this drug on KSHV viral load in plasma.
- Correlate viral load with viral gene expression and/or tumor regression in these patients.
OUTLINE: This is a multicenter, pilot study.
Patients receive liposomal daunorubicin citrate IV days 1 and 15. Treatment repeats every 4 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity.
Biopsies are performed at baseline and once during treatment to evaluate Kaposi's sarcoma- associated herpes virus (KSHV) viral gene expression in tumors and skin tissue using reverse transcriptase-quantitative polymerase chain reaction. Blood samples are collected at baseline and periodically during treatment to evaluate KSHV viral gene expression in peripheral blood mononuclear cells and viral load in plasma.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
![](https://webarchive.library.unt.edu/web/20130225174124im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed Kaposi's sarcoma (KS) involving the following:
- Skin
- Lymph nodes (palpable disease only)
- Oral cavity
- Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions
- Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy
- Serologically confirmed HIV positivity
Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options
- Must be on a stable dose for ≥ 4 weeks
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 3 months
- No other neoplasia requiring cytotoxic therapy
- Not pregnant or nursing
- Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior anthracycline therapy
At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:
- Chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- Radiotherapy
- Local therapy
- Biological therapy
- Investigational therapy
- At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment
- No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment
![](https://webarchive.library.unt.edu/web/20130225174124im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Florida | |
University of Miami Sylvester Comprehensive Cancer Center - Miami | |
Miami, Florida, United States, 33136 | |
Brazil | |
Instituto De Infectologia Emilio Ribas Hospital | |
Cerqueira Cesar - Sao Paulo/SP, Brazil, 01246-900 | |
Centro de Referencia e Tratamento DST/AIDS | |
Sao Paulo, Brazil, 04121000 |
Study Chair: | Juan Carlos Ramos, MD | University of Miami Sylvester Comprehensive Cancer Center |
Study Chair: | Dirk Dittmer, PhD | UNC Lineberger Comprehensive Cancer Center |
Principal Investigator: | Tamara Newman Lobato Souza | Instituto De Infectologia Emilio Ribas Hospital |
Principal Investigator: | Luis Carlos Pereira, MD | Instituto De Infectologia Emilio Ribas Hospital |
![](https://webarchive.library.unt.edu/web/20130225174124im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | AIDS Malignancy Clinical Trials Consortium |
ClinicalTrials.gov Identifier: | NCT00427414 History of Changes |
Other Study ID Numbers: | CDR0000526564, U01CA070019, AMC-050 |
Study First Received: | January 25, 2007 |
Last Updated: | January 29, 2013 |
Health Authority: | United States: Institutional Review Board Unites States: Federal Government Brazil: Ethics Committee Brazil: Ministry of Health Brazil: National Committee of Ethics in Research |
Keywords provided by AIDS Malignancy Clinical Trials Consortium:
AIDS-related Kaposi sarcoma recurrent Kaposi sarcoma |
Additional relevant MeSH terms:
Sarcoma, Kaposi Sarcoma Herpesviridae Infections DNA Virus Infections Virus Diseases Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type |
Neoplasms Neoplasms, Vascular Tissue Daunorubicin Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on February 24, 2013